Patents by Inventor John R. Falck

John R. Falck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 20-Hete antagonists and agonists
    Patent number: 6596769
    Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),4(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: July 22, 2003
    Assignee: MCW Research Foundation
    Inventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
  • Methods and products relating to 16-HETE analogs
    Patent number: 6562988
    Abstract: The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: May 13, 2003
    Assignees: Univ. Vermont and State Agricultural College, Univ. of Texas System Board of Regents, New York Medical College
    Inventors: John R. Falck, Martin M. Bednar, Cordell E. Gross, Michael Balazy
  • Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
    Patent number: 6552084
    Abstract: Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders are disclosed.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: April 22, 2003
    Assignee: Alcon Universal Ltd.
    Inventors: Peter G. Klimko, Mark R. Hellberg, John R. Falck, Raymond E. Conrow
  • Methods and products relating to 16-HETE analogs
    Publication number: 20020165262
    Abstract: The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke.
    Type: Application
    Filed: November 9, 2001
    Publication date: November 7, 2002
    Applicant: University of Vermont and State Agricultural College
    Inventors: John R. Falck, Martin M. Bednar, Cordell E. Gross, Michael Balazy
  • 12-HETrE analogs and methods of use thereof
    Publication number: 20020151734
    Abstract: The present invention to 12-HETrE analogs which are agonists and antagonists of 12-HETrE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for treating inflammatory conditions, neovascularization, tumor growth, cancer, ischemic cardiovascular diseases, and ocular conditions.
    Type: Application
    Filed: January 2, 2002
    Publication date: October 17, 2002
    Inventors: Michal Laniado Schwartzman, John R. Falck
  • 20- Hete antagonists and agonists
    Publication number: 20020072534
    Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),4(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),ll(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.
    Type: Application
    Filed: December 14, 2001
    Publication date: June 13, 2002
    Inventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
  • 20-HETE antagonists and agonists
    Patent number: 6395781
    Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: May 28, 2002
    Assignee: MCW Research Foundation
    Inventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
  • 20-HETE antagonists and agonists
    Publication number: 20020049244
    Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z), 8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.
    Type: Application
    Filed: December 14, 2001
    Publication date: April 25, 2002
    Inventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
  • Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
    Publication number: 20020035095
    Abstract: Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders are disclosed.
    Type: Application
    Filed: September 10, 2001
    Publication date: March 21, 2002
    Inventors: Peter G. Klimko, Mark R. Hellberg, John R. Falck, Raymond E. Conrow
  • Methods and products related to 16-HETE analogs
    Patent number: 6359158
    Abstract: The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: March 19, 2002
    Assignees: University of Vermont and State Agricultural College, The University of Texas System Board of Regents, New York Medical College
    Inventors: John R. Falck, Martin M. Bednar, Cordell E. Gross, Michael Balazy
  • Arachidonic acid metabolite, 16-HETE
    Patent number: 6140364
    Abstract: The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE. Methods and products are also provided for treating thromboembolic stroke. The method involves the administration of 16-HETE in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably, the 16-HETE is 16(R)-HETE and the thrombolytic agent is tPA. The product is a pharmaceutical preparation of 16-HETE and a thrombolytic agent and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 26, 1999
    Date of Patent: October 31, 2000
    Assignees: The University of Vermont and State Agricultural College, New York Medical College, Board of Regents The University of Texas System
    Inventors: John R. Falck, Martin M. Bednar, Cordell E. Gross, Michael Balazy
  • Curacin A analogs exhibiting antiproliferative activity against cells
    Patent number: 6057348
    Abstract: Isomers of a cytotoxic compound isolated and purified from a marine cyanobacterium Lyngbya majuscula are disclosed. The compound, termed "curacin D", exhibits substantial biological activity against proliferating cells. Analogs of curacin A also are described, as are formulations that include curacin D and the curacin A analogs. The curacins A-D and analogs of curacin A exhibit antimitotic behavior.
    Type: Grant
    Filed: July 14, 1998
    Date of Patent: May 2, 2000
    Assignee: Oregon State University
    Inventors: William H. Gerwick, John R. Falck, Brian L. Marquez
  • Arachidonic acid metabolite, 16-hete
    Patent number: 5753702
    Abstract: The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE.
    Type: Grant
    Filed: May 22, 1996
    Date of Patent: May 19, 1998
    Assignee: University of Vermont
    Inventors: Martin M. Bednar, Cordell E. Gross, Michael Balazy, John R. Falck
  • Functionalizing carbohydrate derivatives by base-induced .beta.-eliminatiom forming bioactive derivatives containing hydroxy-diene subunits
    Patent number: 5334736
    Abstract: A method to functionalize carbohydrate derivatives by base-induced .beta.-elimination and subsequent olefination to form biologically active products containing .alpha.-hydroxy-diene or .alpha.,.beta.-dihydroxy-diene subunits. Also disclosed are methods to prepare biologically active derivatives of fatty acids containing .alpha.-hydroxy-diene groups and .alpha.,.beta.-dihydroxy-diene groups from derivatives of 2-deoxyfuranoses and derivatives of 2-deoxypyranoses, respectively.
    Type: Grant
    Filed: May 16, 1991
    Date of Patent: August 2, 1994
    Assignee: University of Texas System Board of Regents
    Inventors: Lumin Sun, John R. Falck